Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	56.49	9.17	7.19	40.75	13.95
Short-Term Investments	41.05	4.09	15.86	-	-
Cash & Short-Term Investments	97.54	13.25	23.05	40.75	13.95
Cash Growth	636.06%	-42.51%	-43.44%	192.04%	75500.11%
Receivables	-	-	0.04	0.11	-
Prepaid Expenses	0.8	0.74	0.16	1.5	0.05
Other Current Assets	0.11	0.22	1.12	0.11	0.77
Total Current Assets	98.45	14.21	24.37	42.47	14.78
Property, Plant & Equipment	0.15	0.3	0.57	-	-
Total Assets	98.6	14.51	24.94	42.47	14.78
Accounts Payable	0.94	0.65	1.15	1.09	1.72
Accrued Expenses	2.68	2.26	2.4	2.72	0.63
Short-Term Debt	-	0.38	-	-	0.04
Current Portion of Long-Term Debt	-	-	-	0.25	-
Current Portion of Leases	0.11	0.15	0.15	-	-
Current Unearned Revenue	-	-	-	-	2.33
Total Current Liabilities	3.73	3.44	3.7	4.05	4.72
Long-Term Debt	-	-	-	-	0.28
Long-Term Leases	-	0.09	0.21	-	-
Total Liabilities	3.73	3.53	3.9	4.05	5
Common Stock	0.07	0.01	0	0.03	0.01
Additional Paid-In Capital	189.25	77.87	68.8	68.21	24.81
Retained Earnings	-94.42	-66.9	-47.87	-29.82	-15.03
Comprehensive Income & Other	-0.04	0	0.1	-	-
Shareholders' Equity	94.87	10.98	21.04	38.42	9.78
Total Liabilities & Equity	98.6	14.51	24.94	42.47	14.78
Total Debt	0.11	0.62	0.35	0.25	0.32
Net Cash (Debt)	97.43	12.63	22.7	40.5	13.63
Net Cash Growth	671.44%	-44.36%	-43.95%	197.05%	-
Net Cash Per Share	4.11	2.10	5.37	13.35	9.96
Filing Date Shares Outstanding	74.34	6.48	4.83	4.2	1.68
Total Common Shares Outstanding	69.36	6.19	4.2	4.19	1.68
Working Capital	94.72	10.77	20.68	38.42	10.06
Book Value Per Share	1.37	1.77	5.00	9.16	5.84
Tangible Book Value	94.87	10.98	21.04	38.42	9.78
Tangible Book Value Per Share	1.37	1.77	5.00	9.16	5.84
Machinery	0.1	0.1	0.24	-	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q